Citations

Clear

1526 citation(s) found for "Sun, C".

Prediction of post‐vaccination Guillain‐Barré syndrome using data from a passive surveillance system
Luo, Chongliang , Jiang, Ying , Du, Jingcheng , Re, Vincent Lo , Ellenberg, Susan S. , Tao, Cui , Chen, Yong , Tao, Cui , Tong, Jiayi , Huang, Jing Yang , Poland, Gregory A.

Mayo Clinic

Pharmacoepidemiology and Drug Safety | February 5, 2021 | Volume: 30 | Issue: 5 | Pages: 602-609

10.1002/pds.5196 | PMID 33533072 Get It

AbstractPurposeSevere adverse events (AEs), such as Guillain‐Barré syndrome (GBS) occur rarely after influenza vaccination. We identify highly associated AEs with GBS and develop prediction models for GBS using the US Vaccine Adverse Event Reporting System (VAERS) reports following trivalent influenza vaccination (FLU3).MethodsThis study analyzed 80 059 reports from the US VAERS between 1990 and 2017. Several AEs were identified as highly associated with GBS and were used to develop the prediction model. Some common and mild AEs that were suspected to be underreported when GBS occurred simultaneously were removed from the final model. The analyses were validated using European influenza vaccine AEs data from EudraVigilance.ResultsOf the 80 059 reports, 1185 (1.5%) were annotated as GBS related. Twenty‐four AEs were identified as having strong association with GBS. The full prediction model, using age, sex, and all 24 AEs achieved an area under the receiver operating characteristic (ROC) curve (AUC) of 85.4% (90% CI: [83.8%, 86.9%]). After excluding the nine (e.g., pruritus, rash, injection site pain) likely underreported AEs, the final AUC became 77.5% (90% CI: [75.5%, 79.6%]). Two hundred and one (0.25%) reports were predicted as of high risk of GBS (predicted probability >25%) and 84 actually developed GBS.ConclusionThe prediction performance demonstrated the potential of developing risk‐prediction models utilizing the VAERS cohort. Excluding the likely underreported AEs sacrificed some prediction power but made the model more interpretable and feasible. The high absolute risk of even a small number of AE combinations suggests the promise of GBS prediction within the VAERS dataset.
Cirrhotic Cardiomyopathy Predicts Posttransplant Cardiovascular Disease: Revelations of the New Diagnostic Criteria
Izzy, Manhal , Angirekula, Mounika, Mara, Kristin C. , Lin, Grace , Watt, Kymberly D. , Soldatova, Anna, Sun, Xin , Mara, Kristin, Watt, K D , Mara, Kristin C , Soldatova, Anna M. , Sun, Xin

Mayo Clinic

Liver Transplantation | February 5, 2021 | Volume: 27 | Issue: 6 | Pages: 876-886

10.1002/lt.26000 | PMID 33533556 Get It

The diagnostic criteria for cirrhotic cardiomyopathy (CCM) were recently revised to reflect the contemporary advancements in echocardiographic technology. This study evaluates the prevalence of CCM, according to the new criteria, and its impact on posttransplant cardiovascular disease (CVD). This is a single‐center retrospective matched cohort study of liver transplantation (LT) recipients who underwent LT between January 1, 2008 and November 30, 2017. A total of 3 cohorts with decompensated cirrhosis (nonalcoholic steatohepatitis, alcohol‐related liver disease, or other etiologies) were matched based on age, sex, and year of transplant after excluding patients listed without evidence of hepatic decompensation. CCM was defined, according to 2020 criteria, as having diastolic dysfunction, left ventricular ejection fraction ≤50%, and/or a global longitudinal strain (GLS) absolute value <18%. The study echocardiographers were blinded to the clinical data. Posttransplant CVD included new coronary artery disease, congestive heart failure, atrial and ventricular arrhythmia, and stroke. The study included 141 patients of whom 59 were women. The mean age at LT was 57.8 (±7.6) years. A total of 49 patients (34.8%) had CCM. Patients with CCM were at an increased risk for post‐LT CVD (hazard ratio, 2.57; 95% confidence interval, 1.2‐5.5; P = 0.016). Changes in CCM individual parameters pretransplant, such as GLS, early diastolic transmitral flow to early diastolic mitral annular velocity, and left atrial volume index were associated with an increased risk for posttransplant CVD. CCM, defined by the new diagnostic criteria, affects approximately one‐third of decompensated LT candidates. CCM predicts an increased risk for new CVD following LT. Studies into addressing and follow‐up to mitigate these risks are needed.
A Combined Proteomics and Mendelian Randomization Approach to Investigate the Effects of Aspirin-Targeted Proteins on Colorectal Cancer
Nounu, Aayah , Greenhough, Alexander , Heesom, Kate J. , Richmond, Rebecca C. , Weinstein, Stephanie J. , Baron, John A. , Figueiredo, Jane C. , Lindor, Noralane M. , Casey, Graham , Duijnhoven, Fränzel J.B. van , Gsur, Andrea , Vodička, Pavel , Vodičková, Ludmila, Brenner, Hermann , Chang‐Claude, Jenny , Hoffmeister, Michael , Slattery, Martha L. , Gunter, Marc J. , Kim, Hyeong Rok , Li, Li , Bishop, D. Timothy , Gruber, Stephen B. , Rennert, Gad , Harrison, Tabitha A. , Woods, Michael O. , Schafmayer, Clemens , Guelpen, Bethany Van , Gallinger, Steven , Berndt, Sonja I. , Lindblom, Annika , Wu, Anna H. , White, Emily , Peters, Ulrike , Drew, David A. , Scherer, Dominique , Relton, Caroline L. , Weinstein, Stephanie J , Baron, John A , Platz, Elizabeth A. , van Duijnhoven, Fränzel J B , Gsur, Andrea , Moreno, Victor , Brenner, Hermann , Chang-Claude, Jenny , Hoffmeister, Michael , Sakoda, Lori C , Slattery, Martha L , Schoen, Robert E , Castellví-Bel, Sergi , Kweon, Sun-Seog , Bishop, D Timothy , Buchanan, Daniel D , Giles, Graham G , Gruber, Stephen B , Harrison, Tabitha A , Woods, Michael O , Van Guelpen, Bethany , Hampel, Heather , Pharoah, Paul D P , Wolk, Alicja , Drew, David A , Scherer, Dominique , Rennert, Gad , Gunter, Marc J , Vodicka, Pavel , Lindblom, Annika , Zheng, Jie , Albanes, Demetrius , Hopper, John L. , Newcomb, Polly A. , Marchand, Loı̈c Le , Ulrich, Cornelia M. , Li, Christopher I , Campbell, Peter T. , Moreno, Vı́ctor , Sakoda, Lori C. , Schoen, Robert E. , Castellvı́-Bel, Sergi , Chan, Andrew T. , Zheng, Wei , Buchanan, Daniel D. , Giles, Graham G. , Stadler, Zsofia , Lin, Yi , Keku, Temitope O , Hampel, Heather , Pharoah, Paul D.P. , Wolk, Alicja , Bermejo, Justo Lorenzo , Williams, Ann Caroline

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 28, 2021 | Volume: 30 | Issue: 3 | Pages: 564-575

10.1158/1055-9965.epi-20-1176 | PMID 33318029 Get It

Abstract Background: Evidence for aspirin's chemopreventative properties on colorectal cancer (CRC) is substantial, but its mechanism of action is not well-understood. We combined a proteomic approach with Mendelian randomization (MR) to identify possible new aspirin targets that decrease CRC risk. Methods: Human colorectal adenoma cells (RG/C2) were treated with aspirin (24 hours) and a stable isotope labeling with amino acids in cell culture (SILAC) based proteomics approach identified altered protein expression. Protein quantitative trait loci (pQTLs) from INTERVAL (N = 3,301) and expression QTLs (eQTLs) from the eQTLGen Consortium (N = 31,684) were used as genetic proxies for protein and mRNA expression levels. Two-sample MR of mRNA/protein expression on CRC risk was performed using eQTL/pQTL data combined with CRC genetic summary data from the Colon Cancer Family Registry (CCFR), Colorectal Transdisciplinary (CORECT), Genetics and Epidemiology of Colorectal Cancer (GECCO) consortia and UK Biobank (55,168 cases and 65,160 controls). Results: Altered expression was detected for 125/5886 proteins. Of these, aspirin decreased MCM6, RRM2, and ARFIP2 expression, and MR analysis showed that a standard deviation increase in mRNA/protein expression was associated with increased CRC risk (OR: 1.08, 95% CI, 1.03–1.13; OR: 3.33, 95% CI, 2.46–4.50; and OR: 1.15, 95% CI, 1.02–1.29, respectively). Conclusions: MCM6 and RRM2 are involved in DNA repair whereby reduced expression may lead to increased DNA aberrations and ultimately cancer cell death, whereas ARFIP2 is involved in actin cytoskeletal regulation, indicating a possible role in aspirin's reduction of metastasis. Impact: Our approach has shown how laboratory experiments and population-based approaches can combine to identify aspirin-targeted proteins possibly affecting CRC risk.
Decision Support for Tactical Combat Casualty Care Using Machine Learning to Detect Shock
Amos‐Binks, Adam , Burris, Christie, Keeney, Natalie, Pinevich, Yuliya , Pickering, Brian W. , Rule, Gregory , Laufersweiler, Dawn, Sun, Mei, Nemeth, Christopher , Herasevich, Vitaly

Mayo Clinic

Military Medicine | January 25, 2021 | Volume: 186 | Issue: Supplement_1 | Pages: 273-280

10.1093/milmed/usaa275 | PMID 33499479 Get It

ABSTRACT Introduction The emergence of more complex Prolonged Field Care in austere settings and the need to assist inexperienced providers’ ability to treat patients create an urgent need for effective tools to support care. We report on a project to develop a phone-/tablet-based decision support system for prehospital tactical combat casualty care that collects physiologic and other clinical data and uses machine learning to detect and differentiate shock manifestation. Materials and Methods Software interface development methods included literature review, rapid prototyping, and subject matter expert design requirements reviews. Machine learning algorithm methods included development of a model trained on publicly available Medical Information Mart for Intensive Care data, then on de-identified data from Mayo Clinic Intensive Care Unit. Results The project team interviewed 17 Army, Air Force, and Navy medical subject matter experts during design requirements review sessions. They had an average of 17 years of service in military medicine and an average of 4 deployments apiece and all had performed tactical combat casualty care on live patients during deployment. Comments provided requirements for shock identification and management in prehospital settings, including support for indication of shock probability and shock differentiation. The machine learning algorithm based on logistic regression performed best among other algorithms we tested and was able to predict shock onset 90 minutes before it occurred with better than 75% accuracy in the test dataset. Conclusions We expect the Trauma Triage, Treatment, and Training Decision Support system will augment a medic’s ability to make informed decisions based on salient patient data and to diagnose multiple types of shock through remotely trained, field deployed ML models.
Administrative Coding in Electronic Health Care Record‐Based Research of NAFLD: An Expert Panel Consensus Statement
Hagström, Hannes , Adams, Leon A. , Allen, Alina M. , Byrne, Christopher D. , Chang, Yoosoo , Grønbæk, Henning , Jepsen, Peter , Kanwal, Fasiha , Kramer, Jennifer R. , Lazarus, Jeffrey V. , Newsome, Philip N. , Ryu, Seungho , Schattenberg, Jörn M. , Simon, Tracey G. , Tapper, Elliot B. , Yılmaz, Yusuf , Zelber‐Sagi, Shira , Åberg, Fredrik , Kramer, Jennifer , Lazarus, Jeffrey V , Long, Michelle T , Newsome, Philip N , Rowe, Ian A , Schattenberg, Jörn M , Simon, Tracey G , Tapper, Elliot B , Wong, Vincent Wai-Sun , Åberg, Fredrik , Allen, Alina M , Yilmaz, Yusuf , Hagström, Hannes , Ismail, Mona Hassan , Long, Michelle T. , Loomba, Rohit , Serper, Marina , Sheron, Nick , Wild, Sarah H. , Wong, Vincent Wai‐Sun

Mayo Clinic

Hepatology | January 24, 2021 | Volume: 74 | Issue: 1 | Pages: 474-482

10.1002/hep.31726 | PMID 33486773 Get It

Background and Aims Electronic health record (EHR)‐based research allows the capture of large amounts of data, which is necessary in NAFLD, where the risk of clinical liver outcomes is generally low. The lack of consensus on which International Classification of Diseases (ICD) codes should be used as exposures and outcomes limits comparability and generalizability of results across studies. We aimed to establish consensus among a panel of experts on ICD codes that could become the reference standard and provide guidance around common methodological issues. Approach and Results Researchers with an interest in EHR‐based NAFLD research were invited to collectively define which administrative codes are most appropriate for documenting exposures and outcomes. We used a modified Delphi approach to reach consensus on several commonly encountered methodological challenges in the field. After two rounds of revision, a high level of agreement (>67%) was reached on all items considered. Full consensus was achieved on a comprehensive list of administrative codes to be considered for inclusion and exclusion criteria in defining exposures and outcomes in EHR‐based NAFLD research. We also provide suggestions on how to approach commonly encountered methodological issues and identify areas for future research. Conclusions This expert panel consensus statement can help harmonize and improve generalizability of EHR‐based NAFLD research.
Silmitasertib (CX-4945) in combination with gemcitabine and cisplatin as first-line treatment for patients with locally advanced or metastatic cholangiocarcinoma: A phase Ib/II study.
Bai, Li‐Yuan , Chen, Ming‐Huang , Mody, Kabir , Richards, Donald , Davis, S. Lindsey, Huang, Chi-En C-E, Tse, Emmett, Ahn, Daniel H. , Chang, Heung-Moon, Oh, Do‐Youn , Becerra, Carlos, Chen, Yen‐Yang , Borad, Mitesh J. , Hubbard, Joleen M. , Rha, Sun Young , Soong, John, Yen, Chia‐Jui , Park, Joon Oh , Hsu, Chiun , Chen, Jen‐Shi

Mayo Clinic

Journal of Clinical Oncology | January 22, 2021 | Volume: 39 | Issue: 3_suppl | Pages: 312-312

10.1200/jco.2021.39.3_suppl.312 Get It

312 Background: Silmitasertib (CX-4945), an oral small molecule inhibitor of casein kinase 2 (CK2), has exhibited preclinical antitumor activity and strong synergism with gemcitabine + cisplatin. We investigated the safety and efficacy of silmitasertib in combination with gemcitabine + cisplatin in patients with unresectable cholangiocarcinoma (CCA). Methods: S4-13-001 is a multicenter, open-label, phase Ib/II study of silmitasertib in combination with gemcitabine + cisplatin in patients with locally advanced or metastatic CCA. The phase Ib portion included dose-escalation, expansion, and exploratory cohorts of silmitasertib with doses ranging from 200 to 1000 mg bid (6 days for the escalation/expansion cohorts and 10 and 21 days’ continuous dosing for the exploratory cohorts). In the phase II portion patients received silmitasertib 1000 mg bid for 10 days in combination with gemcitabine + cisplatin on days 1 & 8 over a 21-day cycle. In this interim analysis, we present findings from the combined population of patients from the phase Ib and II portions of the study. Response to treatment was assessed by RECIST v1.1 every 6 weeks. Primary efficacy outcome measure was progression-free survival (PFS). ClinicalTrials.gov (NCT02128282). Results: A total of 87 patients were enrolled and received silmitasertib in the phase Ib (n=50) and phase II (n=37) portions of the study. Of these, 55 patients were evaluable for efficacy with details as follows: median PFS 11.1 (95% CI 7.6–14.7) months; median overall survival (OS) 17.4 (95% CI 13.4–25.7) months; overall response rate (ORR) 32.1%; and disease control rate (DCR) 79.3%. Almost all patients (79/87; 90.8%) evaluable for safety reported ≥1 treatment-related adverse event (TEAE). The most common TEAEs (all grades) with silmitasertib were diarrhea (65.5%), nausea (50.6%), vomiting (33.3%), fatigue (31.0%), and anemia (21.8%). The most common grade ≥3 TEAEs were diarrhea (13.8%), neutropenia (11.5%), nausea (9.2%), anemia (8.0%), and thrombocytopenia (8.0%). Eleven patients (12.6%) discontinued treatment due to TEAEs. Conclusions: Silmitasertib in combination with gemcitabine + cisplatin yields promising preliminary evidence of efficacy in patients with locally advanced or metastatic CCA. Based on these data a randomized phase III trial is planned. Clinical trial information: NCT02128282.
Construct Validation of the American Board of Anesthesiology’s APPLIED Examination for Initial Certification
Zhou, Yan , Chen, Dandan , Harman, Ann E., Isaak, Robert S. , Peterson-Layne, Cathleen, Macario, Alex, Fahy, Brenda G. , Wang, Ting , Sun, Huaping , Warner, David O.

Mayo Clinic

Anesthesia & Analgesia | January 21, 2021 | Volume: 133 | Issue: 1 | Pages: 226-232

10.1213/ane.0000000000005364 | PMID 33481404 Get It

BACKGROUND: The American Board of Anesthesiology administers the APPLIED Examination as a part of initial certification, which as of 2018 includes 2 components—the Standardized Oral Examination (SOE) and the Objective Structured Clinical Examination (OSCE). The goal of this study is to investigate the measurement construct(s) of the APPLIED Examination to assess whether the SOE and the OSCE measure distinct constructs (ie, factors). METHODS: Exploratory item factor analysis of candidates’ performance ratings was used to determine the number of constructs, and confirmatory item factor analysis to estimate factor loadings within each construct and correlation(s) between the constructs. RESULTS: In exploratory item factor analysis, the log-likelihood ratio test and Akaike information criterion index favored the 3-factor model, with factors reflecting the SOE, OSCE Communication and Professionalism, and OSCE Technical Skills. The Bayesian information criterion index favored the 2-factor model, with factors reflecting the SOE and the OSCE. In confirmatory item factor analysis, both models suggest moderate correlation between the SOE factor and the OSCE factor; the correlation was 0.49 (95% confidence interval [CI], 0.42-0.55) for the 3-factor model and 0.61 (95% CI, 0.54-0.64) for the 2-factor model. The factor loadings were lower for Technical Skills stations of the OSCE (ranging from 0.11 to 0.25) compared with those of the SOE and Communication and Professionalism stations of the OSCE (ranging from 0.36 to 0.50). CONCLUSIONS: The analyses provide evidence that the SOE and the OSCE measure distinct constructs, supporting the rationale for administering both components of the APPLIED Examination for initial certification in anesthesiology.
A 5-lncRNA Signature Associated with Smoking Predicts the Overall Survival of Patients with Muscle-Invasive Bladder Cancer
Sheng, Haoyue , Zhang, Guiming , Huang, Yongqiang, Sun, Lijiang , Shi, Guohai , Ye, Dingwei

Mayo Clinic

Disease Markers | January 18, 2021 | Volume: 2021 | Issue: No issue available | Pages: 1-10

10.1155/2021/8839747 | PMID 33688381 Get It

Increasing evidence demonstrated that noncoding RNA is abnormally expressed in cancer tissues and serves a vital role in tumorigenesis, tumor development, and metastasis. The aim of the present study was to determine an lncRNA signature in order to predict the overall survival (OS) of patients with muscle-invasive bladder cancer (MIBC). A total of 246 patients with pathologically confirmed MIBC in The Cancer Genome Atlas (TCGA) dataset were recruited and included in the present study. We choose patients who have smoked less (including never smoking) or more than 15 years. A total of 44 differentially expressed lncRNAs were identified with a fold change larger than 1.5 and a P value < 0.05 through the limma package. Subsequently, a comparison between patients with no tobacco smoke exposure for <15 years and patients who had been exposed to tobacco smoke for >15 years was performed by using the matchIt package. Among the 44 differentially expressed lncRNAs, 5 lncRNAs were identified to be significantly associated with OS. Based on the characteristic risk scores of these 5 lncRNAs, patients were divided into low-risk and high-risk groups and exhibited significant differences in OS. Multivariate Cox regression analysis demonstrated that the 5-lncRNA signature was independent of age, tumor-node metastasis (TNM) staging, lymphatic node status, and adjuvant postoperative radiotherapy. In the present study, a novel 5-lncRNA signature was developed and was demonstrated to be useful in predicting the survival of patients with MIBC. If validated, this lncRNA signature may assist in the selection of a high-risk subpopulation that requires more aggressive therapeutic intervention. The risk scores involved in several associated pathways were identified using gene set enrichment analysis (GSEA). However, the clinical implications and mechanism of these 5 lncRNAs require further investigation.
APOE ɛ4 Allele Testing and Risk of Alzheimer Disease
Choudhury, Parichita , Choudhury, Parichita , Ramanan, Vijay K. , Boeve, Bradley F.

Mayo Clinic

JAMA | January 14, 2021 | Volume: 325 | Issue: 5 | Pages: 484

10.1001/jama.2020.15085 | PMID 33443531 Get It

Anesthesiology Residents’ Experiences and Perspectives of Residency Training
Chen, Dandan , Zhou, Yan , Nemergut, Edward C., Macario, Alex, Keegan, Mark T. , Sun, Huaping , Warner, David O.

Mayo Clinic

Anesthesia & Analgesia | January 14, 2021 | Volume: 132 | Issue: 4 | Pages: 1120-1128

10.1213/ane.0000000000005316 | PMID 33438965 Get It

BACKGROUND: Anesthesiology residents’ experiences and perspectives about their programs may be helpful in improving training. The goals of this repeated cross-sectional survey study are to determine: (1) the most important factors residents consider in choosing an anesthesiology residency, (2) the aspects of the clinical base year that best prepare residents for anesthesia clinical training, and what could be improved, (3) whether residents are satisfied with their anesthesiology residency and what their primary struggles are, and (4) whether residents believe their residency prepares them for proficiency in the 6 Accreditation Council for Graduate Medical Education (ACGME) Core Competencies and for independent practice. METHODS: Anesthesiologists beginning their US residency training from 2013 to 2016 were invited to participate in anonymous, confidential, and voluntary self-administered online surveys. Resident cohort was defined by clinical anesthesia year 1, such that 9 survey administrations were included in this study—3 surveys for the 2013 and 2014 cohorts (clinical anesthesia years 1–3), 2 surveys for the 2015 cohort (clinical anesthesia years 1–2), and 1 survey for the 2016 cohort (clinical anesthesia year 1). RESULTS: The overall response rate was 36% (4707 responses to 12,929 invitations). On a 5-point Likert scale with 1 as “very unimportant” and 5 as “very important,” quality of clinical experience (4.7–4.8 among the cohorts) and departmental commitment to education (4.3–4.5) were rated as the most important factors in anesthesiologists’ choice of residency. Approximately 70% of first- and second-year residents agreed that their clinical base year prepared them well for anesthesiology residency, particularly clinical training experiences in critical care rotations, anesthesiology rotations, and surgery rotations/perioperative procedure management. Overall, residents were satisfied with their choice of anesthesiology specialty (4.4–4.5 on a 5-point scale among cohort-training levels) and their residency programs (4.0–4.1). The residency training experiences mostly met their expectations (3.8–4.0). Senior residents who reported any struggles highlighted academic more than interpersonal or technical difficulties. Senior residents generally agreed that the residency adequately prepared them for independent practice (4.1–4.4). Of the 6 ACGME Core Competencies, residents had the highest confidence in professionalism (4.7–4.9) and interpersonal and communication skills (4.6–4.8). Areas in residency that could be improved include the provision of an appropriate balance between education and service and allowance for sufficient time off to search and interview for a postresidency position. CONCLUSIONS: Anesthesiology residents in the United States indicated they most value quality of clinical training experiences and are generally satisfied with their choice of specialty and residency program.